CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation January 23, 2020
CEO Dr. Nader Pourhassan, Ph.D, discusses CytoDyn’ new $87.5 million licensing deal for commercializing Leronlimab to treat HIV, as well as the company’s latest progress for its leronlimab monoclonal antibody drug platform, and it’s pipeline targeting HIV, multiple cancer indications, and immune-mediated illnesses, such as GvHD and NASH, which have blockbuster revenue potential.
CYDY’s lead drug candidate, leronlimab (PRO 140) for treating HIV, is expected to receive FDA approval in mid 2020. Investors attention is also on the possibility of CytoDyn’s HIV monotherapy potential receiving FDA approval as label expansion, potentially in 2021.
CytoDyn’s monotherapy is a potential “game changer” in HIV treatment, requiring only once-weekly dose which could be self-administered.
CYDY stock has increased from $0.35 at the time of the company’s November 14, NEXT SUPER STOCK conference presentation to a recent high of $1.18 – an increase of over 237%.
